[{"data":1,"prerenderedAt":146},["ShallowReactive",2],{"content-site-settings":3,"content-index-en":45},{"id":4,"extension":5,"meta":6,"stem":43,"__hash__":44},"dataFiles\u002Fdata\u002Fsite.json","json",{"en":7},{"siteDetails":8,"cookieControl":12,"siteLogo":16,"mainNav":21,"preNav":32,"stickyNav":33,"footerContent":34},{"organisationName":9,"siteName":10,"siteUrl":11},"Scancell Ltd","The ModiFY Study","https:\u002F\u002Fmodi-1-study.digitrial.com\u002F",{"cookieModalTitle":13,"cookieModalText":14,"nonNecessaryCookiesUsed":15},"Cookies used on this site","This website only uses non-necessary cookies to remember where you are in the process and to learn about how people view the information. We do NOT use cookies that directly identify anyone. For the best experience please click Accept all below.",true,{"url":17,"alt":18,"width":19,"height":20},"modify-logo@2x.png","Home",156.44,80,[22,25,29],{"title":23,"url":24},"Taking part","\u002Ftaking-part",{"title":26,"url":27,"target":28,"external":28},"About the study","\u002Fabout\u002F",false,{"title":30,"url":31,"target":28,"external":28},"Contact","\u002Fcontact\u002F",[],[],{"footerLogo":35,"footerCol1":39,"footerCol2":40,"footerCol3":41,"additionalInfo":42},{"url":36,"alt":37,"width":38,"height":38},"modify-logo-alt@2x.png","Scancell study logo",null,"Email: [modifyenquiries@scancell.co.uk](mailto:modifyenquiries@scancell.co.uk)\n\nTel: +44 (0)1865 582690","Scancell Ltd,\\\nBellhouse Building,\\\nSanders Road,\\\nOxford Science Park,\\\nOxford,\\\nOX4 4GD","[Privacy policy](\u002Fprivacy)\n[Cookie policy](\u002Fcookies)\n[Accessibility statement](\u002Faccessibility)\n[Site map](\u002Fsite-map)","This is a digitrial site made by morph.co.uk.","data\u002Fsite","wJ7sB88ZpZ4Gz5LpO4H3iQkv7sKS81LNYZ210IMhAb0",{"id":46,"title":47,"body":38,"description":38,"extension":5,"meta":48,"navigation":15,"path":142,"seo":143,"stem":144,"__hash__":145},"contentPages\u002Fpages\u002Findex.en.json","Home page",{"pageTitle":10,"pageMetadata":49,"page_content":50},{"htmlTitle":10,"htmlDesc":10},[51,66,74,86,95,106],{"type":52,"title":53,"text":54,"image":55,"settings":60,"sectionSettings":62},"page_header","# The ModiFY Study","The ModiFY Study is a first-in-human clinical trial in patients with head and neck cancer, renal cancer, and triple negative breast cancer",{"url":56,"alt":57,"width":58,"height":59},"modify-header-image-3@2x.png","",1100,720,{"imgWidth":61},"half-width",{"sectionLabel":63,"customClass":64,"theme":65},"The DRIFT Study","page_header_bg_2","primary",{"type":67,"text":68,"video":69,"sectionSettings":73},"text_and_video","## The ModiFY study: Overview\n\nThe ModiFY clinical trial, is being conducted in hospitals across the UK, so that researchers can assess whether the Modi-1 vaccine when given to patients with specific cancer types:\n\n1. Is safe at different doses\n2. Can trigger the immune system to fight cancer \n3. Is effective at shrinking tumours \n\nThe clinical trial is recruiting patients with the following advanced cancer types:\n\n1. (HPV negative) Head and Neck Cancer\n2. Renal Cell Cancer \n3. Triple Negative Breast Cancer \n\nThe study is also recruiting patients with Head and Neck Cancer that are planning to undergo surgery. \n\nThe short video below provides more information about the study.",{"vimeoId":70,"videoTitle":71,"videoTranscript":72,"offlineVideo":57},"808361835\u002F68520f5b89","ModiFY Participant Information Animation","The ModiFY Study...is recruiting patients with triple negative breast, head and neck, ovarian or kidney cancers.\n\nThe study will investigate a new immunotherapy, called Modi-1, to see if it can be used safely in these advanced cancers.\n\nModi-1 is a vaccine that contains three peptides. Peptides are small parts of a protein designed to help your immune system fight cancer.\n\nThis is an experimental treatment that may help treat your cancer by triggering an immune response so that your immune system can shrink your tumour.\n\nAs with all drugs there are potential side effects, so your study doctor will monitor you closely throughout the study.\n\nThe ModiFY Study is recruiting approximately 138 patients in up to 20 cancer centres across the UK.\n\nPatients with your type of cancer are invited to participate…if your doctor believes you are eligible for this type of immunotherapy.\n\nIf you are currently receiving a course of checkpoint inhibitors these will continue as planned.\n\nYour doctor will provide you with more information about the study…and if you decide to take part will ask you to sign a consent form.\n\nTaking part in the study is voluntary. You are free to withdraw at any time without giving a reason\n\nIf you do withdraw, or don’t want to take part, you are still offered the same standard of care for your cancer.\n\nAll patients enrolled in the study complete a number of screening examinations for up to 28 days before the treatment.\n\nThis involves visiting the clinic so we can collect information, carry out tests and in some cases take samples.\n\nMost participants will receive Modi-1 5 times within the first 6 months…then once every 3 months for approximately…2 years, or until your doctor decides the treatment is complete. Whichever comes first.\n\nFollow up visits are scheduled at regular intervals…to collect information, take blood tests and carry out scans to monitor your cancer.\n\nAll medical information and any samples collected will be stored or disposed of, legally and securely.\n\nBy taking part in this study you are helping doctors learn more about how to treat cancer.\n\nFor more information... Send us an email or contact your nearest participating hospital.\n\nDetails can be found on our website.",{"sectionLabel":71},{"type":75,"settings":76,"title":78,"text":79,"image":80,"sectionSettings":84},"text_and_image",{"imgWidth":61,"imgPosition":77},"top","## Objectives","Researchers across the UK aim to address the following questions in the ModiFY clinical trial:\n\n* Is Modi-1 vaccination safe at different doses?\n* Are any side effects related to Modi-1 tolerable?\n* How strongly does Modi-1 trigger the immune system to fight cancer?\n* How effective is Modi-1 in shrinking tumours?\n\nPatients will be treated with Modi-1 vaccine on its own (monotherapy), and in combination with a checkpoint inhibitor (CPI) such as pembrolizumab or nivolumab (where these are standard of care).",{"url":81,"alt":57,"width":82,"height":83},"modify-content-image-5.png",460,300,{"sectionLabel":85},"Background",{"type":67,"text":87,"video":88,"sectionSettings":92},"## How does the Modi-1 vaccine work?\n\nThis short video explains how the Modi-1 vaccine works.",{"vimeoId":89,"videoTitle":90,"videoTranscript":91},"808371130\u002Fbc2de8ee0c","Modi-1: How does the Modi-1 vaccine work?","Modi-1 is a vaccine that may help treat your cancer by boosting your immune system to shrink your tumour.\n\nModi-1 contains three peptides, these peptides are also known as antigens. An antigen can be any substance that triggers an immune response in your body.\n\nThe Modi-1 antigens are small parts of a protein designed to help your immune system fight cancer.\n\nOne important group of cells in the immune system are the antigen presenting cells or APCs.\n\nWhen we inject you with Modi-1, the three antigens are taken up by APCs in your blood. The APCs display the three Modi-1 antigens on its cell surface.\n\nAnother important group of cells in the immune system are the T cells. T cells are white blood cells, otherwise also known as lymphocytes.\n\nWhen a T cell sees an APC with the Modi-1 antigens on its surface, it recognises it. This signal causes the T cell to become ‘activated’.\n\nCancer cells can also have the antigens on their surface that look like the three Modi-1 antigens.\n\nWhen activated T cells see these cancer cells, they can then attack and destroy them.",{"textAlign":93,"sectionLabel":94},"left","Modi-1: Mechanism of action",{"type":75,"settings":96,"text":98,"title":99,"image":100,"sectionSettings":104},{"imgWidth":61,"imgPosition":97},"bottom","Oncologists across the UK are recruiting patients to this clinical trial with Head and Neck Cancer, Renal Cell Cancer and Triple Negative Breast Cancer. If you are not currently receiving treatment or are starting treatment with a checkpoint inhibitor, for any one of these cancer types and are interested to learn more about the ModiFY study please inform your cancer doctor and\u002For the research team at the e-mail address: modifyenquiries@scancell.co.uk.","## Status",{"url":101,"width":102,"height":103},"modify-content-image-15.png",920,600,{"textAlign":93,"sectionLabel":105},"Status",{"type":107,"settings":108,"cards":110,"sectionSettings":140},"text_and_cards",{"headerLevel":109,"headerFontSize":109,"maxCardsPerRow":109,"wholeClickable":15,"numberedCards":28,"alignCards":93,"alignCardContent":93},"3",[111,122,131],{"type":112,"image":113,"title":117,"summary":118,"links":119},"card_image_text",{"url":114,"width":115,"height":116},"modify-card-image-1@2x.png",900,576,"Taking Part","Find out more about what will happen if you decide to take part",[120],{"title":121,"url":24,"external":28,"target":28},"Go to 'Taking Part'",{"type":112,"image":123,"title":125,"summary":126,"links":127},{"url":124,"width":115,"height":116},"modify-card-image-2@2x.png","About the Study","Learn more about the ModiFY Study",[128],{"title":129,"url":130},"Got to 'About the Study'","\u002Fabout",{"type":112,"image":132,"title":134,"summary":135,"links":136},{"url":133,"width":115,"height":116},"modify-card-image-3@2x.png","Contact Us","Do you have any questions or would like to speak to a member of the research team?",[137],{"title":138,"url":139},"Get in touch","\u002Fcontact",{"sectionLabel":141},"Benefits of screening for type 1 diabetes:","\u002Fpages\u002Findex.en",{"title":47},"pages\u002Findex.en","EGj6qP67RAyDN3sITYFEJ7CTqn8W_2Y-2Mi6Adg65r4",1789146654268]